2026 Trials

MANUSCRIPT 2026 Trials:

Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer’s disease: a qualitative interview study.

File Type: www
Categories: 2026
Tags: ACU193, INTERCEPT-AD, Patient Outcomes, TwentyTwentySix